Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy

A.M. McDonnell; W.J. Lesterhuis; A. Khong; A.K. Nowak; R.A. Lake; A.J. Currie; B.W.S. Robinson

doi:10.1002/eji.201444722

Back

Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy

Journal article

Open access

Peer reviewed

Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy

A.M. McDonnell, W.J. Lesterhuis, A. Khong, A.K. Nowak, R.A. Lake, A.J. Currie and B.W.S. Robinson

European Journal of Immunology, Vol.45(1), pp.49-59

2014

DOI: https://doi.org/10.1002/eji.201444722

Files and links (2)

pdf

tumor-infiltrating_dendritic_cells.pdfDownload View

Author’s Version Open Access

url

Free to Read *No subscription requiredView

Abstract

Cross-presentation defines the unique capacity of an APC to present exogenous Ag via MHC class I molecules to CD8+ T cells. DCs are specialized cross-presenting cells and as such have a critical role in antitumor immunity. DCs are routinely found within the tumor microenvironment, but their capacity for endogenous or therapeutically enhanced cross-presentation is not well characterized. In this study, we examined the tumor and lymph node DC cross-presentation of a nominal marker tumor Ag, HA, expressed by the murine mesothelioma tumor AB1-HA. We found that tumors were infiltrated by predominantly CD11b+ DCs with a semimature phenotype that could not cross-present tumor Ag, and therefore, were unable to induce tumor-specific T-cell activation or proliferation. Although tumor-infiltrating DCs were able to take, process, and cross-present exogenous cell-bound and soluble Ags, this was significantly impaired relative to lymph node DCs. Importantly, however, systemic chemotherapy using gemcitabine reversed the defect in Ag cross-presentation of tumor DCs. These data demonstrate that DC cross-presentation within the tumor microenvironment is defective, but can be reversed by chemotherapy. These results have important implications for anticancer therapy, particularly regarding the use of immunotherapy in conjunction with cytotoxic chemotherapy.

Details

Title: Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy
Authors/Creators: A.M. McDonnell (Author/Creator) - The University of Western Australia
W.J. Lesterhuis (Author/Creator) - The University of Western Australia
A. Khong (Author/Creator) - The University of Western Australia
A.K. Nowak (Author/Creator) - The University of Western Australia
R.A. Lake (Author/Creator) - The University of Western Australia
A.J. Currie (Author/Creator) - Murdoch University
B.W.S. Robinson (Author/Creator) - The University of Western Australia
Publication Details: European Journal of Immunology, Vol.45(1), pp.49-59
Publisher: John Wiley & Sons Ltd.
Identifiers: 991005542774407891
Copyright: © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Murdoch Affiliation: School of Veterinary and Life Sciences
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

315 File views/ downloads

146 Record Views

70 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.6 Immunology; 1.6.358 Dendritic Cell Therapy
Web Of Science research areas: Immunology
ESI research areas: Immunology